TASIN-30

Overview

TASIN-30 is a selective EBP inhibitor with an EC 50 of 0.097 μM. TASIN-30 blocks the production of 7-dehydrocholesterol ( 7-DHC ) and downstream cholesterol biosynthesis processes. TASIN-30 depletes downstream sterols, disrupts the integrity of lipid rafts in tumor cells, accelerates intracellular cholesterol consumption, and inhibits tumor cell proliferation. TASIN-30 induces ferroptosis and apoptosis by reducing 7-DHC levels and increasing phospholipid peroxidation. TASIN-30 achieves tumor suppression in nude mice with osteosarcoma. TASIN-30 can be used in cancer-related research such as colorectal cancer and osteosarcoma.

Application

Products | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Colorectal Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Emopamil Binding Protein | Products > Signaling Pathways > Ferroptosis | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-164561
• CAS No.: 1678515-93-9
• Molecular Formula: C18H30N2O3S
• Molecular Weight: 354.51
• Purity: 99.96%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution
• Availability: In-stock

Source

Original product source